Advertisement

Medical Oncology

, 36:61 | Cite as

Expression of cellular apoptosis susceptibility (CAS) in the human testis and testicular germ cell tumors

  • Jianni Liu
  • Mei Ye
  • Ruigang Han
  • Yaoting Gui
  • Xiaofeng Li
  • Han Zhang
  • Xin Wang
  • Haoran Guo
  • Fanghong Li
  • Allan Zijian Zhao
  • Kunping GuanEmail author
  • Hao ChenEmail author
Short Communication
  • 83 Downloads

Abstract

Testicular germ cell tumors are the most frequent malignancies found in men between 15 and 44 years old. Although cellular apoptosis susceptibility (CAS) was demonstrated to be upregulated in breast cancer and colon cancer, the expression of CAS in the human testis and testicular germ cell tumors remained elusive. In the present study, CAS-positive signals were detected in the normal testicular tissues, cancer adjacent normal testicular tissues, seminoma, yolk sac tumor, and teratoma. Interestingly, the expression level of CAS in testicular germ cell tumors (TGCTs) (but not seminoma) was significantly lower than that of human testicular tissues and cancer adjacent normal testicular tissues, suggesting that decreased CAS contributed to the progression of TGCTs. Notably, the expression of CAS in seminoma was significantly higher than that of in the non-seminomas, consistent with the results from TCGA database. Furthermore, the localization of CAS is mainly restricted in the nucleus in the lesions of normal human testicular tissue and cancer adjacent normal testicular tissue. Although the expression of CAS was not significantly different between normal testicular tissue and seminoma, CAS was more enriched in cytoplasm in seminoma compared to the normal, cancer adjacent tissue and other types of TGCTs. The current results demonstrated reduced expression of CAS in the human testicular germ cell tumors and the CAS translocation from the nuclear to cytoplasm in seminoma, thereby supporting a possible role in normal testis function and in the development of seminoma.

Keywords

CAS Testicular germ cell tumors 

Notes

Author contributions

HC and KPG conceived and designed the experiments. JNL, RGH, MY, HZ, XW, and HRG performed the experiments and analyzed the data. YTG and XFL collected the TGCTs. FHL and ZJZ gave intellectual advice and revised the manuscript. JNL and HC wrote the paper.

Funding

This work was supported in part by grants from the National Key Research and Development Program of China (Grant No. 2018YFC1003600); National Natural Science Foundation of China (Grant Nos. 81671432, 81871202); Health and Medical Research Fund of Hong Kong (Grant No. 06170476); and the startup R&D funding of Guangdong University of Technology (Grant No. 220418118).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The project was approved by the Ethic Committee of The Second Hospital of Shanxi Medical University.

Supplementary material

12032_2019_1281_MOESM1_ESM.pptx (186 kb)
Supplementary material 1 (PPTX 185 kb)

References

  1. 1.
    Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, Looijenga LHJ. Testicular cancer. Nat Rev Dis Primers. 2018;4:29.CrossRefGoogle Scholar
  2. 2.
    Diez-Torre A, Silvan U, Wever OD, Bruyneel E. Germinal tumor invasion and the role of the testicular stroma. Int J Dev Biol. 2004;48:545–57.CrossRefGoogle Scholar
  3. 3.
    Jiang MC. CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy. Tumour Biol. 2016;37:13077–90.CrossRefGoogle Scholar
  4. 4.
    Tanaka T, Ohkubo S, Tatsuno I, Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell. 2007;130:638–50.CrossRefGoogle Scholar
  5. 5.
    Holzer K, Drucker E, Oliver S, Winkler J, Eiteneuer E, Herpel E, Breuhahn K, Singer S. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: a potential link to the BRAFV600E mutation. Int J Oncol. 2016;48:1679–87.CrossRefGoogle Scholar
  6. 6.
    Winkler J, Roessler S, Sticht C, DiGuilio AL, Drucker E, Holzer K, Eiteneuer E, Herpel E, Breuhahn K, Gretz N, Schirmacher P, Ori A, Singer S. Cellular apoptosis susceptibility (CAS) is linked to integrin β1 and required for tumor cell migration and invasion in hepatocellular carcinoma. Oncotarget. 2016;7:22883–92.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhu J-H, Hong D-F, Song Y-M, Sun L-F, Wang Z-F, Wang J-W. Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells. Asian Pac J Cancer Prev. 2013;14:1017–21.CrossRefGoogle Scholar
  8. 8.
    Pimiento JM, Neill KG, Henderson-Jackson E, Eschrich SA, Chen DT, Husain K, Shibata D, Coppola D, Malafa MP. Knockdown of CSE1L gene in colorectal cancer reduces tumorigenesis in vitro. Am J Pathol. 2016;186:2761–8.CrossRefGoogle Scholar
  9. 9.
    Liao CF, Luo SF, Li LT, Lin CY, Chen YC, Jiang MC. CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J Exp Clin Cancer Res. 2008;27:15.CrossRefGoogle Scholar
  10. 10.
    Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer. 2006;119:599–607.CrossRefGoogle Scholar
  11. 11.
    Yuksel UM, Turker I, Dilek G, Dogan L, Gulcelik MA, Oksuzoglu B. Does CSE1L overexpression affect distant metastasis development in breast cancer? Oncol Res Treat. 2015;38:431–4.CrossRefGoogle Scholar
  12. 12.
    Yuksel UM, Dilek G, Dogan L, Gulcelik MA, Berberoglu U. The relationship between CSE1L expression and axillary lymph node metastasis in breast cancer. Tumori. 2015;101:194–8.CrossRefGoogle Scholar
  13. 13.
    Wang C, Zhang J, Fok KL, Tsang LL, Ye M, Liu J, Li F, Zhao AZ, Chan HC, Chen H. CD147 induces epithelial-to-mesenchymal transition by disassembling cellular apoptosis susceptibility protein/E-cadherin/beta-catenin complex in human endometriosis. Am J Pathol. 2018;188:1597–607.CrossRefGoogle Scholar
  14. 14.
    Chang C-C, Tai C-J, Su T-C, Shen K-H, Lin S-H, Yeh C-M, Yeh K-T, Lin Y-M, Jiang M-C. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas. Ann Diagn Pathol. 2012;16:362–8.CrossRefGoogle Scholar
  15. 15.
    Mane DR, Kale AD, Belaldavar C. Validation of immunoexpression of tenascin-C in oral precancerous and cancerous tissues using ImageJ analysis with novel immunohistochemistry profiler plugin: an immunohistochemical quantitative analysis. J Oral Maxillofac Pathol: JOMFP. 2017;21:211–7.CrossRefGoogle Scholar
  16. 16.
    Alnabulsi A, Agouni A, Mitra S, Garcia-Murillas I, Carpenter B, Bird S, Murray GI. Cellular apoptosis susceptibility (chromosome segregation 1-like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. J Pathol. 2012;228:471–81.CrossRefGoogle Scholar
  17. 17.
    Lorenzato A, Martino C, Dani N, Oligschlager Y, Ferrero AM, Biglia N, Calogero R, Olivero M, Di Renzo MF. The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB J. 2012;26:2446–56.CrossRefGoogle Scholar
  18. 18.
    Liao CF, Lin SH, Chen HC, Tai CJ, Chang CC, Li LT, Yeh CM, Yeh KT, Chen YC, Hsu TH, et al. CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells. Mol Med. 2012;18:1269–80.CrossRefGoogle Scholar
  19. 19.
    Kutay U, Bischoff FR, Kostka S, Kraft R, Görlich D. Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell. 1997;90:1061–71.CrossRefGoogle Scholar
  20. 20.
    Dong Q, Li X, Wang CZ, Xu S, Yuan G, Shao W, Liu B, Zheng Y, Wang H, Lei X, et al. Roles of the CSE1L-mediated nuclear import pathway in epigenetic silencing. Proc Natl Acad Sci USA. 2018;115:E4013–22.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jianni Liu
    • 1
    • 2
  • Mei Ye
    • 1
  • Ruigang Han
    • 3
  • Yaoting Gui
    • 4
  • Xiaofeng Li
    • 4
  • Han Zhang
    • 2
  • Xin Wang
    • 2
  • Haoran Guo
    • 2
  • Fanghong Li
    • 1
  • Allan Zijian Zhao
    • 1
  • Kunping Guan
    • 2
    Email author
  • Hao Chen
    • 1
    Email author
  1. 1.School of Biomedical and Pharmaceutical SciencesGuangdong University of TechnologyGuangzhouPeople’s Republic of China
  2. 2.Second Hospital of ShanXi Medical UniversityTaiyuanPeople’s Republic of China
  3. 3.Reproductive Medicine Center of The 306th Hospital of PLABeijingPeople’s Republic of China
  4. 4.Department of Laboratory MedicinePeking University Shenzhen HospitalShenzhenPeople’s Republic of China

Personalised recommendations